Navigation Links
Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
Date:7/1/2009

ul>

About REALIZE

In this single-center, open-label, uncontrolled, pilot study, 50 women undergoing ovarian stimulation prior to IVF or ICSI were down-regulated with daily injections of 0.1 mg of GnRH agonist (starting on cycle day 21). Ovarian stimulation was started with a single dose of corifollitropin alfa (100 mcg or 150 mcg) followed by daily rFSH (follitropin beta) from stimulation day eight until the day of triggering oocyte maturation. Final oocyte maturation was induced by administration of hCG as soon as three follicles 17 mm or greater were present. Vaginal progesterone was administered for luteal phase support. Patients with proven poor response were excluded from participation. The main endpoint of this trial was ovarian response. The observed number of follicles, serum estradiol levels and number of oocytes indicated a relatively high ovarian response. Corifollitropin alfa was well tolerated and there were no serious adverse events or cases of OHSS.(6)

Key Findings

  • Both the 100 mcg and 150 mcg dose groups recruited a large number of follicles 11 mm or greater with mean (SD) values of 17.5 (+/-5.5) and 18.3 (+/-6.4), respectively on the day of hCG and median serum estradiol levels of 10,019 and 10,221 pmol/L, respectively.(6)
  • The mean (SD) number of oocytes retrieved per started cycle was 15.4 (+/-6.7) in the 100 mcg dose group and 17.8 (+/-5.1) in the 150 mcg dose group.(6)

About corifollitropin alfa

Corifollitropin alfa is an investigational product being developed as a potential treatment in Controlled Ovarian Stimulation (COS) for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program. Corifollitropin alfa is designed as a sustained follicle stimulant (SFS) with the same pharmacodynamic profile as rFSH, but with a markedly prolonged duration
'/>"/>

SOURCE Schering-Plough
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...Nov. 5 WaferGen Biosyste...eloper of state-of-the-art genetic analysis system...as joined the company,s Scientific Advisory Board....mercializing novel molecular diagnostics for cance...elopment of computational biology systems for seve...
(Date:11/5/2009)... LASIK Surgery and vision correction experts lis...ctively involved at the recently concluded America...ng in San Francisco, California. Dr. Stephen Brint...Davidorf, MD, Dr. Peter Rapoza, MD, Dr. Michael Ra...wman, MD, Dr. Edward Manche, MD, and Dr. Parag Maj...
(Date:11/4/2009)... Nov. 4 DIATHERIX Laboratories, In...ented at the Michigan Security Network Homeland Se...ich. Dennis Grimaud, Chairman and Chief Executive ...company,s advanced molecular diagnostic testing on...isease diagnosis and military efforts. ,, "Thi...
(Date:11/4/2009)...., Nov. 4 Nektar Therape...l results for the third quarter ended September 30...ember 30, 2009 improved to $31.0 million or $0.33 ...ion or $0.40 per share in the third quarter of 200...to its operating efficiencies as compared to a yea...
Breaking Biology Technology:WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 2Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 3Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 5Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 6Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 7Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 8Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 9DIATHERIX Laboratories Presents at Homeland Security Conference 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 3Nektar Therapeutics Reports Third Quarter 2009 Financial Results 4Nektar Therapeutics Reports Third Quarter 2009 Financial Results 5Nektar Therapeutics Reports Third Quarter 2009 Financial Results 6Nektar Therapeutics Reports Third Quarter 2009 Financial Results 7Nektar Therapeutics Reports Third Quarter 2009 Financial Results 8Nektar Therapeutics Reports Third Quarter 2009 Financial Results 9Nektar Therapeutics Reports Third Quarter 2009 Financial Results 10
...t Wisconsin Thompson tells BIO attendees , , E... cheerleader, former governor and current Secretar... the featured lunch keynote speaker Monday at the ...n Francisco. Thompson took the podium after San Fr...d to not forget San Francisco and locate and start...
... long been a home of innovation for entrepreneurs,...e it an attractive place for them to place their r...n Madison over the past decade, the citys potentia... first on the list of best areas for business and ...roject in mind when they start, such as Opgen s a...
...s editor discusses nanotech trends at conference ...nference last week at the University of Wisconsin-... industry behind making really small stuff said Wi...luster in innovation. , ,Steve Crosby, editor of t... reason to know: the magazine has worked with the ...
Other Biology Technology:WTN Interview: HHS Secretary calls for $550 million health care fund to reduce deaths caused by medical errors 2WTN Interview: HHS Secretary calls for $550 million health care fund to reduce deaths caused by medical errors 3The NeuronFarm works to increase reading comprehension 2The NeuronFarm works to increase reading comprehension 3The NeuronFarm works to increase reading comprehension 4Wisconsin places high in nanotech venture capital, average in innovation 2
(Date:11/4/2009)... Heavy traffic corridors in the cities of Long Bea... proportion of preventable childhood asthma, and t... on the disease has likely been underestimated, ac...rn California (USC). , The study, which appears...Public Health , estimated that nine percent of all...
(Date:11/4/2009)... The Singapore laboratory that deciphered the DNA ...h) and elephant shark, has joined The Genome 10K P...able repository of DNA sequences on 10,000 species...a scale that currently can not be achieved. , Pa...n a paper published in the Nov. 5, 2009 issue of t...
(Date:11/4/2009)..., MADISON, N.J., Oct. 20 /PRNewswire-FirstCall/...the world,s leading provider of diagnostic testing... third quarter ended September 30, 2009, income fr...$1.02 per diluted share, from $160 million, or $0....8. In 2008, third quarter results were reduced by ...
Breaking Biology News(10 mins):USC study finds big air pollution impacts on local communities 2Singapore scientists join international study of 10,000 vertebrates' genomes 2Quest Diagnostics Reports Strong Performance in Third Quarter 2009 2Quest Diagnostics Reports Strong Performance in Third Quarter 2009 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 4Quest Diagnostics Reports Strong Performance in Third Quarter 2009 5Quest Diagnostics Reports Strong Performance in Third Quarter 2009 6Quest Diagnostics Reports Strong Performance in Third Quarter 2009 7Quest Diagnostics Reports Strong Performance in Third Quarter 2009 8Quest Diagnostics Reports Strong Performance in Third Quarter 2009 9Quest Diagnostics Reports Strong Performance in Third Quarter 2009 10Quest Diagnostics Reports Strong Performance in Third Quarter 2009 11Quest Diagnostics Reports Strong Performance in Third Quarter 2009 12Quest Diagnostics Reports Strong Performance in Third Quarter 2009 13Quest Diagnostics Reports Strong Performance in Third Quarter 2009 14Quest Diagnostics Reports Strong Performance in Third Quarter 2009 15Quest Diagnostics Reports Strong Performance in Third Quarter 2009 16Quest Diagnostics Reports Strong Performance in Third Quarter 2009 17Singapore Witnesses Healthy Growth in Diagnostics Industry 59192 1Singapore Witnesses Healthy Growth in Diagnostics Industry 59192 2Singapore Witnesses Healthy Growth in Diagnostics Industry 59192 3TargetEx Leads the European Cancer Research Consortium 14404 1TargetEx Leads the European Cancer Research Consortium 14404 2Calibration Free Supersaturation Assessment and Control for the Development and Optimization of Crystallization Processes 14401 1Calibration Free Supersaturation Assessment and Control for the Development and Optimization of Crystallization Processes 14401 2
...once credited with magical healing powers but are ...oses but the cause of numerous diseases such as di...gests this view ignores the vital role played by m...and the great therapeutic potential they have. , ...y the European Science Foundation (ESF) on the cur...
...n. 16, 2008) -- The National Heart, Lung, and Bloo...n grant to the Center of Vascular Biology at Weill...edical research into vascular disease -- specifica...r risk factors for coronary artery disease, heart ...arded to Drs. Katherine and David Hajjar represent...
...uary 16, 2008) The latest medications can delay t... to reverse its devastating effects. This limitati...rs patients maintaining a good quality of life for...ped by the Georgia Institute of Technology and Emo...inexpensive test that could be administered as par...
Other Biology News:ESF's workshop restores good name of sugar 2ESF's workshop restores good name of sugar 3$13 million federal grant for research into vascular disease awarded to Weill Cornell 2Portable device quickly detects early Alzheimer's 2Portable device quickly detects early Alzheimer's 3
Anti-Bunyavirus (G1) Monoclonal Antibody, Unconjugated, Clone 8C2.1 from CHEMICON
Quantikine mRNA Base Kit from R&D Systems
...nal carcinoma of testis and ovary but not other ty...ithelium of yolk sac tumor and immature teratoma a...h and acini cells of pancreas and lobules of breas...on on human embryonal carcinoma cells. Immunogen...
Chicken Anti-Ras-related C3 botulinum toxin substrate 1 Polyclonal Antibody, Unconjugated from GenWay Biotech, Inc.
Biology Products: